天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>57046-73-8

57046-73-8

中文名稱 (ALPHAZ)-ALPHA-(3-吡啶基亞甲基)-1H-吲哚-3-乙腈
英文名稱 Paprotrain
CAS 57046-73-8
分子式 C16H11N3
分子量 245.28
MOL 文件 57046-73-8.mol
57046-73-8 結(jié)構(gòu)式 57046-73-8 結(jié)構(gòu)式

基本信息

中文別名
(ALPHAZ)-ALPHA-(3-吡啶基亞甲基)-1H-吲哚-3-乙腈
英文別名
Paprotrain
2-(1H-Indol-3-yl)-3-pyridin-3-yl-acrylonitrile
(Z)-α-(3-Pyridinylmethylene)-1H-indole-3-acetonitrile
1H-Indole-3-acetonitrile, α-(3-pyridinylmethylene)-, (αZ)-
(alphaZ)-alpha-(3-Pyridinylmethylene)-1H-indole-3-acetonitrile

物理化學(xué)性質(zhì)

熔點(diǎn)202℃
儲存條件Sealed in dry,2-8°C
溶解度DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:6): 0.1 mg/ml; Ethanol: 0.2 mg/ml
形態(tài)粉末
顏色Light yellow to yellow
(ALPHAZ)-ALPHA-(3-吡啶基亞甲基)-1H-吲哚-3-乙腈價格(試劑級)
報價日期產(chǎn)品編號產(chǎn)品名稱CAS號包裝價格
2024/11/08HY-101298(ALPHAZ)-ALPHA-(3-吡啶基亞甲基)-1H-吲哚-3-乙腈
Paprotrain
57046-73-85mg500元
2024/11/08HY-101298(ALPHAZ)-ALPHA-(3-吡啶基亞甲基)-1H-吲哚-3-乙腈
Paprotrain
57046-73-810mM * 1mLin DMSO550元
2024/11/08HY-101298(ALPHAZ)-ALPHA-(3-吡啶基亞甲基)-1H-吲哚-3-乙腈
Paprotrain
57046-73-810mg700元

常見問題列表

生物活性
Paprotrain是可滲透細(xì)胞的kinesin MKLP-2 的抑制劑,抑制 MKLP-2 的 ATPase 活性,IC50 值為 1.35 μM,Ki 值為 3.36 μM,同時對 DYRK1A 有中等的抑制作用,IC50值為 5.5 μM。
靶點(diǎn)

MKLP-2

1.35 μM (IC 50 )

體外研究

Paprotrain has been screened on a panel of CNS kinases. While inactive (IC 50 >10 μM) on CDK5 and GSK3, it has shown a moderate activity on DYRK1A (IC 50 =5.5 μM). Time-lapse microscopy shows that disrupting MKlp2 expression with paprotrain results in polar body extrusion failure. This could be rescued after rescuing oocytes from paprotrain in fresh medium. Cell cycle analysis shows that most oocytes are arrested at metaphase I or telophase I. However, oocyte spindle structure and chromosome alignment are not disrupted after the inhibition of MKlp2 by paprotrain. Paprotrain-treated porcine oocytes suffer failure of nuclear maturation. The number of oocytes arrested at early MI stage increase in a dose-dependent manner after KIF20A activity inhibition, while the percentage of oocytes that reach ATI and MII stages decrease after treatment.

"57046-73-8" 相關(guān)產(chǎn)品信息
1192-37-6 98-92-0